Shares of Axon Enterprise, Inc. (NASDAQ:AXON – Get Rating) have been assigned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $186.13.
A number of research analysts have recently commented on the stock. Morgan Stanley increased their target price on shares of Axon Enterprise from $130.00 to $155.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 13th. Credit Suisse Group raised their price objective on shares of Axon Enterprise from $152.00 to $200.00 and gave the company an “outperform” rating in a report on Tuesday, January 10th. StockNews.com assumed coverage on shares of Axon Enterprise in a report on Wednesday, October 12th. They issued a “hold” rating for the company. Northland Securities raised their price objective on shares of Axon Enterprise from $140.00 to $160.00 in a report on Wednesday, November 9th. Finally, Robert W. Baird raised their price objective on shares of Axon Enterprise from $170.00 to $200.00 in a report on Thursday, December 15th.
Axon Enterprise Trading Down 0.1 %
Shares of Axon Enterprise stock opened at $191.46 on Tuesday. The company has a market capitalization of $13.63 billion, a price-to-earnings ratio of 132.04 and a beta of 0.79. The company has a quick ratio of 2.39, a current ratio of 2.79 and a debt-to-equity ratio of 0.01. Axon Enterprise has a 12-month low of $82.49 and a 12-month high of $198.40. The firm’s 50-day moving average price is $177.87 and its two-hundred day moving average price is $148.32.
Axon Enterprise (NASDAQ:AXON – Get Rating) last announced its quarterly earnings data on Tuesday, November 8th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.24. The firm had revenue of $311.75 million for the quarter, compared to the consensus estimate of $276.99 million. Axon Enterprise had a net margin of 9.75% and a return on equity of 9.88%. On average, analysts forecast that Axon Enterprise will post 0.54 earnings per share for the current fiscal year.
Insider Transactions at Axon Enterprise
In other news, COO Joshua Isner sold 275 shares of the firm’s stock in a transaction that occurred on Thursday, December 1st. The shares were sold at an average price of $177.96, for a total transaction of $48,939.00. Following the completion of the sale, the chief operating officer now owns 237,576 shares of the company’s stock, valued at approximately $42,279,024.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Matthew R. Mcbrady sold 1,699 shares of Axon Enterprise stock in a transaction on Friday, November 11th. The shares were sold at an average price of $182.88, for a total value of $310,713.12. Following the completion of the sale, the director now owns 5,651 shares of the company’s stock, valued at approximately $1,033,454.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Joshua Isner sold 275 shares of Axon Enterprise stock in a transaction on Thursday, December 1st. The shares were sold at an average price of $177.96, for a total transaction of $48,939.00. Following the completion of the sale, the chief operating officer now directly owns 237,576 shares of the company’s stock, valued at approximately $42,279,024.96. The disclosure for this sale can be found here. Insiders sold a total of 347,827 shares of company stock valued at $65,476,161 in the last quarter. 6.90% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Axon Enterprise
Several large investors have recently bought and sold shares of the stock. Natixis Advisors L.P. lifted its stake in Axon Enterprise by 31.5% during the 4th quarter. Natixis Advisors L.P. now owns 31,246 shares of the biotechnology company’s stock valued at $5,184,000 after acquiring an additional 7,479 shares in the last quarter. State of Michigan Retirement System raised its stake in shares of Axon Enterprise by 1.2% during the 4th quarter. State of Michigan Retirement System now owns 17,180 shares of the biotechnology company’s stock worth $2,851,000 after purchasing an additional 200 shares during the period. Oregon Public Employees Retirement Fund raised its stake in shares of Axon Enterprise by 1.2% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 19,903 shares of the biotechnology company’s stock worth $3,303,000 after purchasing an additional 228 shares during the period. Comerica Bank raised its stake in shares of Axon Enterprise by 4.7% during the 4th quarter. Comerica Bank now owns 116,975 shares of the biotechnology company’s stock worth $21,578,000 after purchasing an additional 5,234 shares during the period. Finally, Strs Ohio bought a new stake in shares of Axon Enterprise during the 4th quarter worth $799,000. 75.62% of the stock is currently owned by institutional investors.
Axon Enterprise Company Profile
Axon Enterprise, Inc engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Axon Enterprise, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Axon Enterprise wasn’t on the list.
While Axon Enterprise currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
